Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907933 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4915676 | 1.00 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4917681 | 0.92 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6400808 | 0.92 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL7232230 | 0.92 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4919789 | 0.92 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL6228141 | 0.92 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL7668745 | 0.91 | TACR1 (0.98) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6406208 | 0.91 | TACR1 (0.98) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6405905 | 0.91 | TACR1 (0.98) | TACR1CYP2D6KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1032571-B1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2002-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | HRH2, TACR1, HRH4 | TACR1 2/4885CYP2D6 507/4885KCNH2 300/4885 |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | TACR1, HRH2, GRPR | TACR1 1/4885CYP2D6 451/4885KCNH2 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.